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Galectin-3 is a carbohydrate-binding protein and regulates diverse 
functions, including cell proliferation and differentiation, mRNA 
splicing, apoptosis induction, immune surveillance and inflam-
mation, cell adhesion, angiogenesis, and cancer-cell metastasis. 
Galectin-3 is also recommended as a diagnostic or prognostic 
biomarker of various diseases, including heart disease, kidney 
disease, and cancer. Galectin-3 exists as a cytosol, is secreted 
in extracellular spaces on cells, and is also detected in nuclei. 
It has been found that galectin-3 has different functions in 
cellular localization: (i) Extracellular galectin-3 mediates cell 
attachment and detachment. (ii) cytosolic galectin-3 regulates 
cell survival by blocking the intrinsic apoptotic pathway, and 
(iii) nuclear galectin-3 supports the ability of the transcriptional 
factor for target gene expression. In this review, we focused on 
the role of galectin-3 on translocation from cytosol to nucleus, 
because it happens in a way independent of carbohydrate 
recognition and accelerates cancer progression. We also sug-
gested here that intracellular galecin-3 could be a potent 
therapeutic target in cancer therapy. [BMB Reports 2020; 
53(4): 173-180]
INTRODUCTION
Galectin-3, as a member of the galectin family, which are rec-
ognized -galactoside-containing glycoconjugates by means of 
carbohydrate-recognition domain (CRD) (1, 2). Based on 
molecular structure, galectin family consists of the 15 members 
and these family are divided into three main groups: 1) 
prototype group (Galectin-1, -2, -5, -7, -10, -11,-13, -14, and 
-15), 2) tandem repeat group (galectin-4, -6, -8, -9, and -12), 
and 3) chimera type (galectin-3) (1, 3-6). Whereas prototype 
galectins are mostly homodimers with two polypeptides each 
containing a CRD, the tandem repeat galectins have two 
CRDs, connected by a linker region (1, 4, 5). Chimeric galectin-3 
consist of one CRD connected to an extended Proline-Glycine- 
Tyrosine tandem repeats region and an N-terminal proline and 
glycine rich domain (3, 5). Galectin family are present in a 
various tissues, whereas others have a more specific location 
(1). Galectins have many functions, such as cell proliferation 
and differentiation, immune response, apoptosis, cancer 
progression, and metastasis (4, 7). The mechanisms underlying 
these aspects are currently the focus of massive research 
projects.
Galectin-3 is the only chimera type in animal lectins. Also, 
galectin-3 is one of the most studied of the galectin family, 
(8-10). It is a versatile 29–35 kDa protein, as an involved in 
multiful biological processes followed in cellular location: cell 
adhesion, cell growth and differentiation, the cell cycle, and 
apoptosis (1, 11, 12). Galectin-3 is situated on chromosome 
14, locus q21–q22 which is coded by a single gene LGALS3 
(13). LGALS3 gene promoter region have a several regulatory 
elements, like a Sp1 binding sites, AP-1 complex, cAMP- 
dependent response element (CRE) motifs, and two NF-kB-like 
sites (10, 11). Galectin-3 mainly exists in the cytosol and is 
secreted out to the extracellular membrane (ECM) (14), but 
galectin-3 is also reported in the nucleus and mitochondria (9, 
15). 
In galectin family, it is known that there is no signal peptide 
to guide you through the classical secretion pathway. In par-
ticular, galectin-3 to go in extracellular space can interact with 
multiple binding partners or generality polylactosamine-rich 
molecules in the extracellular matrix (ECM) or on the surface 
of cells, and plays a major role in the extracellular regulation 
of various cancer progression (5, 16, 17). The non-classical 
secretion mechanism for galectin-3 remains unclear, but recently 
acquired data show that the secreted galactin-3 is regulated by 
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exosomes (18) and that the N-terminal domain serves to 
position the galactin-3 in these structures (6, 10, 19). 
Galectin-3 is also present in the nucleus and cytosol. Espe-
cially, depending on the various cell types and specific experi-
mental conditions, galectin-3 has been reported to be predom-
inantly located in the cytosol and nuclei or distributed between 
the two subcellular compartments (1, 20). Many articles have 
supported galectin-3 localization, transport, and association 
with the interaction of distinct subcellular components (1, 20).
Through the in this review, we were described brief over-
view of the intracellular galectin-3 functions in cancer pro-
gression that are independent of carbohydrate recognition and 
nucleus or cytoplasmic shuttling. 
REGULATION OF GALECTIN-3 EXPRESSION IN 
CANCERS
Despite of expression of galectin-3 in various of tissues and 
cell types, and their involvement in various human diseases, 
this molecule is of particular interest due to its remarkable role 
in controlling cancer progression (21, 22). Galectin-3 is often 
high expressed in various solid and malignant tumors, and this 
case is generally correlated with the progression of cancer, 
suggesting that this molecule plays an important role in disease 
outcome (4, 5). In particular, the expression of galectin-3 in 
cells is characterized by the following malignant cell trans-
formation (23), tumor growth (24), cell adhesion (25), anoikis 
resistance (26, 27), pro- or anti-apoptosis (28-30), angiogenesis 
(31-33), and cell motility (34-36) have been reported. Galectin-3 
expression may also be a potential biomarker of various cancers 
(37). Interestingly, expression of galectin-3 was implicated in 
many cancers (16, 38). Especially, highly expression of 
galectin-3 was detected in stomach, liver, esophagus, thyroid, 
and pancreas cancers (23, 39-44). This highly expressed 
galectin-3 is correlated with cancer progression or metastatic 
potential in various cancers (38, 45). However, contradictory 
results have also been reported, in which the expression of 
galectin-3 was significantly reduced in breast, prostate and 
endometrial cancers (46-49). In addition, expression of galectin-3 
has also been reported to be up-regulated at an early stage of 
intrahepatic cholangiocarcinoma and down-regulated at later 
stage of intrahepatic cholangiocarcinoma (50). Also, galectin-3 
translocation from the nucleus to the cytoplasm during prostate 
carcinoma was observed (51). This implies that decreased 
galectin-3 expression may be associated with alterations in 
cytoplasm / nucleus expression patterns and provides a reason 
why studies on translocation as well as the expression of 
galectin-3 in various carcinomas should be continued.
According to many reports, galectin-3 is not a common and 
obvious marker for various cancers, but it can be a useful 
parameter for diagnosis many tumors. Also, both transcriptional 
and translational galectin-3 expression was regulated by various 
stimulations and ligands. In addition, numerous factors have 
an effect on the complex regulatory mechanism of galectin-3 
(1, 7). For example, the expression of galectin-3 in adenoma 
that prolactin and adrenocorticotropic hormone (ACTH) in the 
pituitary gland and other tumors is associated with the 
galectin-3’s promoter methylation status of the galectin-3 (52). 
Also, regulatory mechanism of galectin-3 expression is not 
directly induced by certain factors, but the cellular differentiation 
state or tissue type has been involved. Moreover, various 
transcription factors, as a RUNX (rent-related protein) family, 
nuclear factor kB (NF-kB), homeodomain-interacting protein 
kinase 2 (HIPK2), and many intracellular signal pathways, such 
as Wnt and Notch signaling, are regulated in the regulation of 
galectin-3 expression (11, 53-56).
MECHANISM OF NUCLEUS AND CYTOPLASMIC 
GALECTIN-3 SHUTTLING 
Nucleus and cytoplasmic shuttling is generally reported as the 
repeated bi-directional movement of proteins across nuclear 
pore complex (7, 20, 57). Both nucleus and cytoplasmic 
shuttling of galectin-3 reported by means of the many articles 
(57, 58). The galectin-3 movement between the nucleus and 
the cytoplasm has been the focus of attention for years (7, 17, 
20). This is because the shuttle of galectin-3 from the nucleus 
to the cytoplasm is necessary because it protects certain cells 
from stress challenges (20, 57). Especially, the N-terminal area 
containing the phosphorylated Ser6 site, plays an important 
role in nuclear transport because the mutation in the Ser6 
interferes with the export of galectin-3 by cytoplasm (1, 12, 
59). CRD of galectin-3 is important for carbohydrate bonding, 
but this structural domain is also important for galectin-3 
localization in cells (1, 7, 12). Recently, galectin-3 is seen as 
an important nuclear protein, which may be evidenced by the 
discovery of both nuclear import sequences (nuclear localiza-
tion sequence; NLS) and nuclear export sequences (NES) 
sequences within the CRD (Fig. 1) (1, 4, 20). The combination 
with Importin  is very important for the movement of 
galectin-3 but the Importin / complex is necessary for the 
transport of galecin-3 (60, 61). Also, export of galectin-3 is 
known to rely on the binding to Nucleoporin 98 (Nup98), and 
the Nup98:XPO1 complex is involved in the nuclear migration 
of galectin-3 (62). 
Also, a mutation of galectin-3 at position 64 of amino-acid 
(rs4644) substituting proline for histidine (gal-3H64) increased 
nuclear galectin-3 in breast and gastric cancers (63, 64). 
Moreover, gal-3H64 enhances gastric cancer progression more 
than wild type galectin-3 (gal-3P64) does. gal-3H64 also 
increased both nuclear accumulation of -catenin and 
expression of TCF-4 target genes, such as fascin-1 and c-Myc, 
by means of the augmented promoter-binding activity of TCF-4 
more than did gal-3P64 (63). Thus, galectin-3 shuttling was 
regulated by the domain or mutation in various cancers and 
was involved in cancer progression. 
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Fig. 1. Structure of galectin-3. Galectin-3 consists of an N-terminal Domain (NTD), which has an N-terminal Region of 12 amino acids (aa) 
and a PGAY repeat motif (12-115aa). The carbohydrate-recognition domain (CRD) 130 aa comprises the C-terminal. Each domain describes 
a binding motif and signaling pathway.
Apoptosis regulated by galectin-3 interacts with carbohydrate 
recognition independent manner 
Galectin-3 involved in diverse signal-transduction cascades 
and pro- or anti-survival processes. Actually, phosphorylated 
galectin-3 is required for anti-apoptotic activity and for phos-
phorylation regulated by carbohydrate recognition (9, 12, 17). 
However, those anti-apoptotic functions of galectin-3 were 
regulated by non-carbohydrate recognition. It was proved that 
galectin-3 interacts Bcl-2 (28). Although galectin-3 is not a 
member included in the Bcl-2 family, interestingly, these 
galectin-3 and Bcl-2 genes have significant sequence similarity 
(48% protein sequence similarity) (28). Especially, CRD region 
of galectin-3 have a four-amino-acid motif, as an Asn-Trp-Gly- 
Arg (NWGR) (amino-acid residues 180–183), which motif is 
highly conserved in Bcl-2 family’s BH-1 domain (amino-acid 
residues 143–146 in Bcl-2 gene) (12, 28). Moreover, galectin-3 
is the only member that contains the NWGR motif in the 
galectin family and that acts as an anti-apoptotic molecule in 
intracellular localization. Therefore, the NWGR motif in CRD 
of galectin-3 is closely involved in anti-apoptotic process through 
interaction with Bcl-2. However, galectin-3 regulates apoptosis 
by means of the cytochrome c release and cell-cycle regu-
lation. 
Cancer progression and cell motility regulated by galectin-3 
interacts with carbohydrate recognition independent manner 
As mentioned in the introduction, galectin-3 has many roles in 
various cancers, such as splicing (65), cell proliferation (66), 
regulation of the cell cycle (26), angiogenesis (33), tumori-
genesis (67), and cancer metastasis (68). It has also been 
demonstrated to be highly expressed in various primary and 
metastatic tumors (69) associated with increased cancer progres-
sion, cell motility, and metastasis (4, 70). Actually, galectin-3 
binding with transcription factor (TF) in the nucleus by means 
of the following signaling pathway, such as Wnt, Ras, or MEK, 
as followed various cancer progression (1, 4). In this part, we 
showed that the role of galectin-3 in cancer progression and 
cell motility with regulation of gene transcription focuses on 
our galectin-3-related story. 
Galectin-3 and Fascin-1: For the cancer progression and cell 
motility with galectin-3, we focus on motility-related genes, 
among which fascin-1, an actin-bundling protein, is located 
along the entire length of filopodia in cells (71, 72). Because 
(a) a highly expressed fascin-1 was reported in various cancers 
including gastric, lung, and esophagus cancers (73-75). (b) 
Increased fascin-1 induces membrane protrusions and increases 
cancer cell motility (76). (c) Depletion of fascin-1 leads to a 
substantially reduced number of filopodia and overexpression 
of fascin-1, significantly increasing cell migration (74, 77, 78). 
Especially, fascin-1 expression is regulated by the Wnt-signaling 
pathway. As previously reported, galectin-3 was also reported 
to interact with GSK-3b and b-catenin which is regulate Wnt 
signaling (79). Therefore, galectin-3 regulates b-catenin nuclear 
accumulation via strongly interacting with GSK-3b and the 
binding of b-catenin/TCF-4 to promoter region of fascin-1 (Fig. 
2) (35). Those studies propose that galectin-3 is involved in 
gastric-cancer metastasis and a critical therapeutic target for 
the cancer prevention. 
Galectin-3 and Protease-activated receptor-1 (PAR-1), Matrix 
Metalloprotease (MMP)-1: PAR-1, a cell-surface receptor, is a 
member of the family of transmembrane G-protein-coupled 
receptors (80). Activated PAR-1 is initiated by cleavage at its N 
terminus exodomain between Arg41 and Ser42, and auto- 
phosphorylates to trigger amplification of downstream signaling 
by proteases (80-83), such as thrombin or MMP-1 derived from 
stroma (84). PAR-1 and MMP-1 were related in cancer progres-
sion and cell motility. Interestingly, up-regulation of PAR-1 
and MMP-1 via c-Jun and Fra-1 over-expression also followed, 
AP-1 complex, as a c-Jun and Fra-1, were direct interaction of 
galectin-3 (Fig. 2). It was previously reported that galectin-3 
regulates MUC2 expression via interaction with AP-1, leading 
to its activation, and the site of formation of complexes was 
hypothesized to be AP-1 on the MUC2 promoter (85). Those 
results also support about galectin-3 regulates cancer progres-
sion and motility.
Galectin-3 and Neogenin-1: Neogenin-1 is a transmembrane 
receptor, as a member of immunoglobulin superfamily (86). 
Although neogenin-1 has significant sequence similarity (50% 
amino-acid identity) with the tumor suppressor molecule 
deleted in colon cancer (DCC) (86), but the expression is 
increased in gastric cancer patients (87). Also, neogenin-1 is 
enhanced in cancer proliferation and cell motility (87). 
Actually, expression of neogenin-1 is regulated by heat shock 
factor-1 (HSF-1). Moreover, galectin-3 promotes gastric-cancer 
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Fig. 2. Schematic model of mechanism of galectin-3 in cancer progression and metastasis. Galectin-3 bound various transcription factors, 
such as AP-1, HSF-1, C/EBP, and TCF4/LEF1, and regulates cancer progression and cell motility.
cell motility by means of up-regulation of neogenin-1 expres-
sion by means of the induced phosphorylation of ROCK1(87). 
Additionally, galectin-3 induced accumulation of HSF-1 in 
nuclei by means of direct binding (Fig. 2). Those data suggest 
that galectin-3 is involved in cancer progression. 
Galectin-3 and Hyaluronan-mediated motility receptor (HMMR): 
At last, HMMR binds with hyaluronan on the cell surface, 
where it activates a signal-transduction cascade causing intra-
cellular protein tyrosine phosphorylation (88, 89). In addition, 
HMMR interacts with actin filaments, microtubules, and mitotic 
spindle assemblies, necessary for the organization of the 
cytoskeletal network (88, 90-92). These HMMRs are regulated 
by interaction between the transcriptional factor CCAAT/ 
enhancer-binding protein b (C/EBPb) and galectin-3 (36). Also, 
C/EBPb is regulated by galectin-3BP (galectin-3 binding protein) 
and promotes tumor progression in various cancers (Fig. 2) 
(93-95). These data mean galectin-3 binds with transcription 
factor in nuclei and regulates cancer progression and meta-
stasis.
Senescence regulated by galectin-3 interacts with 
carbohydrate recognition independent manner
By means of the aberrant activation of oncogenes, such as Ras 
and Myc, or excessive mitogenic signals, can enhance 
senescence by means of two different pathways, p14ARF/p53/p21 
or p16INK4A/pRB (96). However, galectin-3 knock-out (KO) 
mouse embryo fibroblasts (MEF) and silenced galectin-3 
gastric-cancer cells showed that galectin-3 relies on p27KIP1, 
not p21wAF1/CIP1, to regulate premature senescence without 
oncogenic stress (97). Actually, the N-terminal of galectin-3 
(amino-acid residues 1–110), bound with Rb, E2F1, as a 
transcription factor of SKP2, was released from Rb and 
initiated its transcriptional functions (Fig. 1) (97). Increased 
SKP2 regulates p27KIP1 degradation. Based on the research, 
galectin-3 prevents premature senescence by means of inter-
action and phosphorylation of Rb and consequent regulation 
of SKP2 and p27KIP1 expression. Moreover, galectin-3 bound to 
human Telomerase Reverse Transcriptase (hTERT) is an impor-
tant factor of tumorigenesis and senescence (98). Especially, 
hTERT plays an important role in the regulation of telomerase 
activity in cell division, which is responsible for immortalized 
cell growth. The hTERT was binding with the N-terminal of 
galectin-3 (amino-acid residues 1–62) and increased telomeric 
activity (Fig. 1) (98). This evidence will show that galectin-3 
regulates cellular senescence by means of the related genes 
interaction.
Cancer stemness regulated by galectin-3 interacts with 
carbohydrate recognition independent manner
Cancer Stem Cells (CSCs) are a malignant and aggressive 
cancer phenotype and have been increasingly studied over the 
last decade. These cells are derived from more differentiated 
cancer cells, potentially acquiring self-renewal properties and 
the ability to undergo epithelial-mesenchymal metastasis (EMT). 
Recently, galectin-3 expression increased in tumor sphere 
formation in cancer cells, together with stem-cell markers 
Oct4, Sox2, Nanog, CD133, and CXCR4 (99). Those mean 
galectin-3 is involved in the stemness of cancer cells. Especially, 
galectin-3 binds with EGF and bFGF (99) as a component of 
stem-cell culture medium and regulates KLF4 expression with 
miRNA-152 (100). These results support that galectin-3 is 
involved in cancer stemness. Also, galectin-3 supports stemness 
by signaling pathway regulation. Galectin-3 was essential for 
cluster formation using v3 integrin and KRAS to activate the 
NF-kB pathway and stemness (101). Also, the Wnt, Notch, and 
SHH signaling pathways can help CSCs properties from 
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normal stem cells. Among the signaling pathways, the Notch 1 
intra-cellular domain (N1ICD) interacts with CRD of galectin-3 
(amino-acid residues 111-250) (Fig. 1) in the cytoplasm of 
ovarian cancer cells (55). Moreover, galectin-3 is interaction 
with -catenin, as a component Wnt signaling pathway, in the 
cytoplasm and help to nuclear accumulation in the gastric 
cancer cells (35, 63). The above results suggest that galectin-3 
regulates cancer stemness by means of the various interaction 
molecules, not only carbohydrates. 
PERSPECTIVES: GALECTIN-3 IS A POTENTIAL 
THERAPEUTIC TARGET FOR CANCER PROGRESSION
Among current research on the role of galectin-3, the 
prognosis value of cancer patients still needs to be discussed 
(5, 102). Nevertheless, the expression of galectin-3 was proved 
to be a useful parameter for the diagnosis and/or prognosis of 
various cancers. (21, 38, 103). Therefore, many researchers 
have attempted to develop new approaches for the diagnosis 
and treatment of cancer by galectin-3 targeting. First, trans-
fected galectin-3 antisense cDNA decreases in the malignant 
phenotype of thyroid gland cancer cells (104). Numerous 
studies have focused on the galectin-3 targeting inhibitors, 
including peptide antagonists (105) and galactose-based inhibitors 
(106, 107). Also, in addition to these synthetic molecules, a 
natural product, pectin, has emerged as a good source for 
generating high-affinity galectin-3 inhibitors with low toxicity. 
Recently, a wide range of sub-molecular inhibitors have been 
considered (108). Among these, a new kind of galectin-3 
inhibitor, which contains only one residue of sugar (109) that 
constitutes membrane permeability and oral available powerful 
galectin-3 inhibitor has been developed.
CONCLUSION
Highly expressed galectin-3 is detected in various cancers and 
tissues, and is involved in many biological processes, like a 
cell proliferation, adhesion, anti- or pro-apoptosis, cancer 
progression, and metastasis. Therefore, galectin-3 is enhanced 
in cancer progression and metastasis by means of different 
mechanisms. Also, the biological function of galectin-3 were 
attributed to each carbohydrate-binding activity. However, 
many articles showed that galectin-3 interacts with many 
molecules by non-carbohydrate binding. In this review, we 
focus on the regulation mechanism with nucleus and cyto-
plasmic shuttling and the role of nuclear galectin-3 in cancer 
progression. Especially, galectin-3 has an NLS and NES; however, 
galectin-3 mutation also helps the galectin-3 shuttling nucleus 
and cytosol. As follows, galectin-3 has many functions in each 
location. Additionally, galectin-3 is involved in cancer progres-
sion and metastasis by means of the binding with transcription 
factor, such as AP-1 complex (c-Jun/Fra-1), HSF-1, C/EBP, and 
TCF4/LEF1. Also, recently many articles supported about multi- 
function of galectin-3 in various cancers and other diseases. 
Those increased understanding evidences give to the galectin-3 
expression or activity regulation mechanism for therapeutic 
purposes. Given these results, we propose that galectin-3 is a 
core protein in cancer progression and metastasis. In addition, 
the function of galectin-3 and the mechanisms by which it can 
be regulated should be understood in detail.
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